

Supplementary Information

Stereospecific Diaza-Cope Rearrangement as an Efficient Tool for the Synthesis of DPEDA Pyridine Analogs and Related C₂-Symmetric Organocatalysts

A.S. Kucherenko, A. A. Kostenko, V.V. Gerasimchuk and S.G. Zlotin*

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospect, 119991 Moscow, Russia



1. Pictures of ¹H and ¹³C NMR spectra for novel compounds

2. ¹H NMR data for known compounds



3. HPLC data

1. Pictures of ^1H and ^{13}C NMR spectra for novel compounds



(1*S*,2*S*)-1,2-Di(pyridin-2-yl)ethane-1,2-diamine (2a):





(1*R*,2*R*)-1,2-Di(pyridin-4-yl)ethane-1,2-diamine (2b):







(1*R*,2*R*)-*N,N'*-Bis[(*R*)-prolyl]-1,2-bis(1-methylpyridin-4-yl)ethane-1,2-diamine bis(triflate)/bis(trifluoroacetate) (*RR*-1*b*):





**(1*R*,2*R*)-*N,N'*-Bis[(*S*)-prolyl]-1,2-bis(1-methylpyridin-4-yl)ethane-1,2-diamine
Bis(triflate)/Bis(trifluoroacetate) (*RS*-1b):**



(R)-4-Hydroxy-4-(quinolin-3-yl)butan-2-one (10d):




(R)-4-Hydroxy-4-(quinolin-4-yl)butan-2-one (10e):




2. ¹H NMR – data for known compounds


4,4',4''-(1H-imidazole-2,4,5-triyl)tripyrindine (5b) [1]: ¹H NMR (300 MHz, d₆-DMSO): δ 8.56-8.54 (d, 2H), 8.51-8.49 (d, Hz, 4H), 7.98–7.96 (d, 2H), 7.53-7.51 (d, 4H), 4.60 (s (*br*), 1H) ppm.




(R)-4-Hydroxy-4-(4-nitrophenyl)butan-2-one (10a): [2] ¹H NMR (500 MHz, CDCl₃): 8.15 (d, 2H), 7.52 (d, 2H), 5.24 (t, 1H), 3.82 (s, (*br*) 1H), 2.85 (d, 2H), 2.21 (s, 3H) ppm.




(R)-4-Hydroxy-4-(2-nitrophenyl)butan-2-one (10b):^[3] ¹H NMR (300 MHz, CDCl₃): 7.99-7.90 (m, 2H), 7.68 (t, 1H), 7.45 (t, 1H), 5.70 (d, 1H), 3.17 – 2.70 (m, 2H), 2.25 (s, 3H) ppm.




(R)-4-(2-bromophenyl)-4-hydroxybutan-2-one (10c):^[2] ¹H NMR (300 MHz, CDCl₃): 7.64 (d, 1H), 7.53 (d, 1H), 7.38 (t, 1H), 7.12 (m, 1H), 5.46 (m, 1H), 3.70 (s, (*br*), 1H), 3.04 – 2.62 (m, 2H), 2.23 (s, 3H) ppm.




(R)-1-Cyclopropyl-3-hydroxy-3-(4-nitrophenyl)propan-1-one (10f):^[4] conversion \approx 50%. ¹H NMR (300 MHz, CDCl₃): 10.16 (s, 1H), 8.40 (d, 2H), 8.19 (d, 2H), 8.08 (d, 2H), 7.56 (d, 2H), 5.26 (m, 1H), 3.75 (s, 1H), 2.99 (m, 2H), 1.92 (m, 1H), 1.30-0.89 (m, 4H) ppm.




(S)-2-((R)-Hydroxy(4-nitrophenyl)methyl)cyclohexanone (10g):^[2] ¹H NMR (300 MHz, CDCl₃): 8.15 (d, 2H), 7.47 (d, 2H), 4.87 (d, 1H), 4.13 (m, 1H), 2.57-2.50 (m, 1H), 2.43-1.32 (m, 8H) ppm.




(S)-2-((R)-Hydroxy(perfluorophenyl)methyl)cyclohexanone (10h):^[5] ¹H NMR (300 MHz, CDCl₃): 5.33-5.30 (d, 1H), 3.91 (s, (*br*), 1H), 3.05-2.96 (m, 1H), 2.55-2.34 (m, 3H), 2.20-2.10 (m, 1H), 1.90-1.80 (m, 1H), 1.70 – 1.15 (m, 3H), 1.40-1.26 (m, 1H) ppm.




(R)-Methyl-2-hydroxy-4-oxo-2-phenylpentanoate (11a):^[6] ¹H NMR (300 MHz, CDCl₃): 7.56 (d, 1H), 7.39-7.28 (m, 4H), 4.42 (s, (*br*), 1H), 3.77 (s, 3H), 3.59 and 3.53 – 3.05 and 2.99 (dd, 2H), 2.21 (s, 3H) ppm.



(S)-Benzyl-2-ethyl-2-hydroxy-4-oxopentanoate (11b):^[6] ¹H NMR (300 MHz, CDCl₃): 7.34 (m, 5H), 5.18 (s, 2H), 3.77 (s, 1H), 3.06-2.77 (dd, 2H), 2.10 (s, 3H), 1.71-1.64 (m, 2H), 0.86 – 0.81 (t, 3H) ppm.




(R)-3-Hydroxy-3-(2-oxopropyl)indolin-2-one (12):^[7] ¹H NMR (300 MHz, CDCl₃): 8.21 (s, (br), 1H), 7.37-7.23 (m, 2H), 7.11-7.05 (m, 1H), 6.91-6.87 (m, 1H), 3.26-2.95 (dd, 2H), 2.19 (s, 3H) ppm.




3. HPLC data




2,2'-((1S,2S)-1,2-di(pyridin-2-yl)ethane-1,2-diyl)bis(azan-1-yl-1-ylidene)bis(methan-1-yl-1-ylidene)diphenol (4a): *Chiralpak AD-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda=220$ nm, $t_{\text{major}} = 30.5$ min, $t_{\text{minor}} = 40.5$ min.





2,2'-((1R,2R)-1,2-di(pyridin-4-yl)ethane-1,2-diyl)bis(azan-1-yl-1-ylidene)bis(methan-1-yl-1-ylidene)diphenol (4b): *Chiralpak AD-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda=220$ nm, $t_{\text{major}} = 26.1$ min, $t_{\text{minor}} = 82.6$ min.




4-hydroxy-4-(4-nitrophenyl)butan-2-one (10a): *Chiralpak OJ-H*, 0.8 mL/min, *n*-hexane/*i*-PrOH =70:30, $\lambda = 254$ nm, $t_1 = 9.8$ min, $t_2 = 10.6$ min.




(R)-4-Hydroxy-4-(2-nitrophenyl)butan-2-one (10b): *Chiralpak AD-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda = 254$ nm, $t_{\text{major}} = 19.2$ min, $t_{\text{minor}} = 20.5$ min.



(R)-4-(2-bromophenyl)-4-hydroxybutan-2-one (10c): *Chiralpak OJ-H*, 0.8 mL/min, *n*-hexane/*i*-PrOH = 90:10, $\lambda = 220$ nm, $t_{\text{major}} = 10.9$ min, $t_{\text{minor}} = 12.6$ min.




No	Retention MIN	Area mV*сек	Area %
1	11.05	1398.66	50.13
2	12.77	1391.44	49.87
2	32.99	2790.09	100.00




No	Retention MIN	Area mV*сек	Area %
1	10.95	11541.11	94.16
2	12.63	715.86	5.84
2	29.23	12256.97	100.00

(R)-4-hydroxy-4-(quinolin-3-yl)butan-2-one (10d): *Chiralpak AD-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 90:10, $\lambda = 220$ nm, $t_{\text{major}} = 22.9$ min, $t_{\text{minor}} = 21.0$ min.




No	Retention MIN	Area mV*сек	Area %
1	19.52	16030.33	49.92
2	21.21	16082.45	50.08
2	39.98	32112.79	100.00




No	Retention MIN	Area mV*сек	Area %
1	20.96	222.72	5.28
2	22.94	3993.13	94.72
2	32.84	4215.85	100.00

(R)-4-hydroxy-4-(quinolin-4-yl)butan-2-one (10e): *Chiralpak OJ-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 90:10, $\lambda = 220$ nm, $t_{\text{major}} = 16.4$ min, $t_{\text{minor}} = 21.6$ min.




No	Retention MIN	Area mV*сек	Area %
1	15.15	39375.37	50.10
2	19.59	39214.67	49.90
2	22.35	78590.04	100.00




No	Retention MIN	Area mV*сек	Area %
1	16.45	14805.46	95.77
2	21.61	654.51	4.23
2	44.79	15459.96	100.00

(R)-1-Cyclopropyl-3-hydroxy-3-(4-nitrophenyl)propan-1-one (10f): *Chiralpak OJ-H*, 0.8 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda = 254$ nm, $t_{\text{major}} = 8.7$ min, $t_{\text{minor}} = 11.8$ min.




No	Retention MIN	Width/2 MIN	Height mV	Height %	Area mV*сек	Area %
1	8.498	0.165	137.57	59.56	1500.52	51.03
2	11.07	0.240	93.41	40.44	1439.80	48.97
2	12.16	0.203	230.98	100.00	2940.32	100.00




No	Retention MIN	Width/2 MIN	Height mV	Height %	Area mV*сек	Area %
1	8.72	0.178	538.88	97.06	6370.68	94.03
2	11.82	0.415	16.30	2.94	404.73	5.97
2	12.57	0.296	555.17	100.00	6775.42	100.00

(S)-2-((R)-hydroxy(4-nitrophenyl)methyl)cyclohexanone (10g): *Chiralpak OJ-H*, 0.8 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda = 254$ nm, $t_{\text{major}} = 8.9$ min, $t_{\text{minor}} = 9.5$ min.




No	Retention MIN	Area mV*сек	Area %
1	8.766	1219.78	44.64
2	9.193	132.97	4.87
3	9.956	1256.12	45.97
4	12.9	123.68	4.53
4	15.77	2732.56	100.00




No	Retention MIN	Width/2 MIN	Height mV	Height %	Area mV*сек	Area %
1	8.758	0.167	170.21	90.99	1892.88	89.59
2	9.175	0.171	4.75	2.54	53.26	2.52
3	9.937	0.183	4.99	2.67	57.38	2.72
4	12.67	0.243	7.11	3.80	109.33	5.17
4	44.75	0.191	187.06	100.00	2112.85	100.00

(S)-2-((R)-hydroxy(perfluorophenyl)methyl)cyclohexanone (10h): *Chiralpak OJ-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 90:10, $\lambda = 254$ nm, $t_{\text{major}} = 4.3$ min, $t_{\text{minor}} = 4.9$ min.





No	Retention MIN	Width/2 MIN	Height mV	Height %	Area mV*сек	Area %
1	4.403	0.125	25.04	49.66	193.92	46.58
2	4.598	0.130	25.38	50.34	222.38	53.42
2	29.99	0.128	50.42	100.00	416.30	100.00





No	Retention MIN	Width/2 MIN	Height mV	Height %	Area mV*сек	Area %
1	4.363	0.117	110.22	99.84	872.97	99.57
2	4.893	0.233	0.17	0.16	3.81	0.43
2	9.917	0.175	110.39	100.00	876.78	100.00

(R)-Methyl-2-hydroxy-4-oxo-2-phenylpentanoate (11a): *Chiralpak AD-H*, 0.7 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda=220$ nm, $t_{\text{major}} = 8.3$ min, $t_{\text{minor}} = 9.4$ min.



(S)-Benzyl-2-ethyl-2-hydroxy-4-oxopentanoate (11b): *Chiralpak AD-H*, 1 mL/min, *n*-hexane/*i*-PrOH = 95:5, $\lambda=210$ nm, $t_{\text{major}} = 14.3$ min, $t_{\text{minor}} = 17.7$ min.



(S)-3-Hydroxy-3-(2-oxopropyl)indolin-2-one (12): *Chiralpak OJ-H*, 0.8 mL/min, *n*-hexane/*i*-PrOH = 70:30, $\lambda = 254$ nm, $t_{\text{major}} = 10.4$ min, $t_{\text{minor}} = 11.7$ min.







Table 1. Optimization of catalyst structure and reaction conditions.^a




Entry	Cat (mol. %)	Solvent	X equiv.	T, h	Yield, 10 %	ee, %
1	(<i>R,S</i>)- 1b (10)	neat	4	25	94	91
2	(<i>R,R</i>)- 1b (10)	neat	4	25	85	86
3	(<i>R,S</i>)- 1b (10)	DCM	4	25	25	81
4	(<i>R,S</i>)- 1b (10)	THF	4	25	20	80
5	(<i>R,S</i>)- 1b (10)	IPS	4	25	48	82
6	(<i>R,S</i>)- 1b (10)	PhMe	4	25	<10	n.d.
7	(<i>R,S</i>)- 1b (10)	EtOAc	4	25	15	77
8	(<i>R,S</i>)- 1b (5)	neat	4	25	85	86
9	(<i>R,S</i>)- 1b (10)	neat	2	30	72	87


^aThe reactions were carried out with catalysts **1b** (5–10 mol%), 4-nitrobenzaldehyde **8a** (0.52 mol, 78.5 mg), acetone **9a** (2–4 equiv, 76.0 - 152 μ L) and solvent (100 μ L) (if applicable) at r.t.



Spectra ^1H NMR of the reaction mixture in the presence of fresh sample of **1b** measured at 3 h time period.



Spectra ^1H NMR of the reaction mixture in the presence of 15-fold used sample of **1b** measured at 3 h time period.



References

- 1 M. V. Proskurnina, N. A. Lozinskaya, S. E. Tkachenko, N. S. Zefirov, *Russ. J. Org. Chem.*, 2002, **38**, 8, 1149.
- 2 S. Luo, H. Xu, J. Li, L. Zhang, J. P. Cheng, *J. Am. Chem. Soc.*, 2007, **129**, 3074.
- 3 S. Fotaras, C. G. Kokotos, E. Tsandi, G. Kokotos, *Eur. J. Org. Chem.*, 2011, 1310.
- 4 Y. Liu, H. Shen, X. Zhang, *Main Group Met. Chem.*, 2012; **35**: 111.
- 5 M. Lombardo, S. Easwar, F. Pasi, C. Trombini., *Adv. Synth. Catal.*, 2009, **351**, 276.
- 6 V. G. Lisnyak, A. S. Kucherenko, E. F. Valeev, S. G. Zlotin., *J. Org. Chem.*, 2015, **80**, 9570.
- 7 B. Wang, J. Zhu, Y. Wei, G. Luo, H. Qu, L.H. Liu, *Synthetic Communications*, 2015, **45**, 2841.